NT-814

Bayer to Acquire UK-Based Biotech KaNDy Therapeutics Ltd.

Retrieved on: 
Tuesday, August 11, 2020

Bayer, a leader in womens healthcare, and KaNDy Therapeutics Ltd, a UK clinical-stage biotech company, announced today that Bayer will acquire KaNDy Therapeutics Ltd. to expand its drug development pipeline in womens healthcare.

Key Points: 
  • Bayer, a leader in womens healthcare, and KaNDy Therapeutics Ltd, a UK clinical-stage biotech company, announced today that Bayer will acquire KaNDy Therapeutics Ltd. to expand its drug development pipeline in womens healthcare.
  • The acquisition of KaNDy Therapeutics Ltd. is another important milestone in augmenting Bayers own womens healthcare portfolio through strategic collaborations and agreements.
  • KaNDy Therapeutics Ltd. is a UK-based private clinical-stage biotech that was founded in 2017 as a spin-off from NeRRe Therapeutics Ltd.
  • KaNDy Therapeutics is based at the state-of-the-art Stevenage Bioscience Catalyst, a leading location for companies to develop and commercialize cutting edge therapeutics.

Forbion Portfolio Company, KaNDy Therapeutics, to Be Acquired by Bayer

Retrieved on: 
Tuesday, August 11, 2020

We are delighted that Bayer has decided to acquire KaNDy and support the ongoing work around the symptoms of menopause.

Key Points: 
  • We are delighted that Bayer has decided to acquire KaNDy and support the ongoing work around the symptoms of menopause.
  • Bayer has been our preferred partner due to its leading position in the area of womens healthcare, said Dr. Mary Kerr, Co-Founder and CEO of KaNDy Therapeutics.
  • Goldman Sachs International is serving as financial advisor to KaNDy Therapeutics Ltd., while Goodwin is serving as legal counsel.
  • Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world.